[go: up one dir, main page]

MX2016000611A - Fusocinas que implican citocinas con una afinidad de union al receptor considerablemente menor. - Google Patents

Fusocinas que implican citocinas con una afinidad de union al receptor considerablemente menor.

Info

Publication number
MX2016000611A
MX2016000611A MX2016000611A MX2016000611A MX2016000611A MX 2016000611 A MX2016000611 A MX 2016000611A MX 2016000611 A MX2016000611 A MX 2016000611A MX 2016000611 A MX2016000611 A MX 2016000611A MX 2016000611 A MX2016000611 A MX 2016000611A
Authority
MX
Mexico
Prior art keywords
fusokines
receptor binding
binding affinities
strongly reduced
reduced receptor
Prior art date
Application number
MX2016000611A
Other languages
English (en)
Other versions
MX375441B (es
Inventor
Tavernier Jan
Bultinck Jennyfer
Sarah Gerlo
Uzé Gilles
Paul Franciane
Bordat Yann
Original Assignee
Vib Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vib Vzw filed Critical Vib Vzw
Publication of MX2016000611A publication Critical patent/MX2016000611A/es
Publication of MX375441B publication Critical patent/MX375441B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con una proteína de fusión que comprende al menos dos citosinas, de las cuales al menos es una citosina modificada con una afinidad de unión considerablemente menor a su receptor o a uno de sus receptores. Preferentemente, ambas citosinas se conectan mediante un enlazador, preferentemente un enlazador GGS. La invención se relaciona además de dicha proteína de fusión para su uso en el tratamiento de enfermedades.
MX2016000611A 2013-07-18 2014-07-03 Fusocinas que implican citocinas con una afinidad de union al receptor considerablemente menor. MX375441B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13306034 2013-07-18
PCT/EP2014/064227 WO2015007536A2 (en) 2013-07-18 2014-07-03 Fusokines involving cytokines with strongly reduced receptor binding affinities

Publications (2)

Publication Number Publication Date
MX2016000611A true MX2016000611A (es) 2016-09-29
MX375441B MX375441B (es) 2025-03-06

Family

ID=48906191

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000611A MX375441B (es) 2013-07-18 2014-07-03 Fusocinas que implican citocinas con una afinidad de union al receptor considerablemente menor.

Country Status (14)

Country Link
US (3) US10640542B2 (es)
EP (2) EP3299466B1 (es)
JP (2) JP6580037B2 (es)
KR (1) KR102322510B1 (es)
CN (2) CN110835376B (es)
AU (2) AU2014292371B2 (es)
BR (1) BR112016001036B1 (es)
CA (1) CA2917937C (es)
DK (1) DK3299466T3 (es)
ES (2) ES2657060T3 (es)
IL (1) IL243451B (es)
MX (1) MX375441B (es)
SG (2) SG10201808738WA (es)
WO (1) WO2015007536A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3371311B1 (en) 2015-11-06 2021-07-21 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
DK3411065T3 (da) 2016-02-05 2021-07-05 Orionis Biosciences BV Clec9a-bindingsmidler
EP3426278B1 (en) 2016-03-07 2024-01-03 Vib Vzw Cd20 binding single domain antibodies
JP7105200B2 (ja) 2016-05-13 2022-07-22 オリオニス バイオサイエンシズ ビーブイ 標的突然変異体インターフェロン－ベータおよびその使用
US11753463B2 (en) 2016-05-13 2023-09-12 Orionis Biosciences BV Therapeutic targeting of non-cellular structures
CA3040802A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
AU2018216032B2 (en) 2017-02-06 2022-04-07 Orionis Biosciences BV Targeted chimeric proteins and uses thereof
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
EP3580230A1 (en) * 2017-02-07 2019-12-18 VIB vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
CN111511763B (zh) 2017-08-09 2024-05-31 奥里尼斯生物科学有限公司 Cd8结合剂
JP7423511B2 (ja) 2017-08-09 2024-01-29 オリオンズ バイオサイエンス インコーポレイテッド Ｐｄ－１およびｐｄ－ｌ１結合物質
US12091463B2 (en) 2017-08-09 2024-09-17 Orionis Biosciences, Inc. Clec9A binding agents comprising a recombinant heavy-chain only antibody (VHH)
JP7551496B2 (ja) 2017-10-31 2024-09-17 カリヴィル イムノセラピューティクス， インコーポレイテッド 全身送達のためのプラットフォーム腫瘍溶解性ベクター
US20200354424A1 (en) 2018-01-26 2020-11-12 Orionis Biosciences, Inc. Xcr1 binding agents and uses thereof
US11896643B2 (en) 2018-02-05 2024-02-13 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
CA3108795A1 (en) 2018-08-08 2020-02-13 Orionis Biosciences, Inc. Sirp1a targeted chimeric proteins and uses thereof
EP3890773A4 (en) 2018-11-08 2022-11-09 Orionis Biosciences, Inc. MODULATION OF DENDRITIC CELL LINES
JP7773371B2 (ja) 2019-03-28 2025-11-19 オリオニス バイオサイエンシズ，インコーポレイテッド Ｃｌｅｃ９ａベースキメラタンパク質複合体
JP7689079B2 (ja) 2019-03-28 2025-06-05 オリオニス バイオサイエンシズ，インコーポレイテッド 治療用インターフェロンアルファ１タンパク質
WO2022011005A1 (en) * 2020-07-07 2022-01-13 Orionis Biosciences, Inc. Immunostimulatory adjuvants
JP2023552289A (ja) 2020-11-19 2023-12-15 カリヴィル イムノセラピューティクス， インコーポレイテッド 腫瘍微小環境リモデリングによる腫瘍溶解性免疫療法
TW202305125A (zh) * 2021-04-30 2023-02-01 美商凱立凡爾免疫治療股份有限公司 用於經修飾mhc表現之溶瘤病毒
US20240166706A1 (en) * 2022-11-21 2024-05-23 Wisconsin Alumni Research Foundation Synthetic il6-il1beta fusion cytokine for promoting t cell cytotoxic function, t cell proliferation, and tumoricidal activity

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0489116B1 (en) * 1989-08-22 1994-04-06 Immunex Corporation Fusion proteins comprising gm-csf and il-3
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
WO2001010912A1 (en) * 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
US20020177571A1 (en) * 2000-11-29 2002-11-28 Gordon Erlinda M. Targeted vectors for cancer immunotherapy
CN1168740C (zh) * 2001-04-04 2004-09-29 上海美恩生物技术有限公司 细胞因子基因修饰的抗原提呈细胞/肿瘤细胞偶联物、其制法和用途
ATE542137T1 (de) * 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
DE602004031341D1 (de) * 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
EP1598364A1 (en) * 2004-05-21 2005-11-23 AGIRx Limited Chimerical soluble hyper IL-11 receptor and use thereof
WO2006053883A1 (en) 2004-11-18 2006-05-26 Vib Vzw Fibronectin iii domain as leptin receptor antagonists
WO2006115800A2 (en) 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
CA2693326A1 (en) * 2006-08-02 2008-02-07 Mcgill University Gm-csf and il-15 fusokines and methods for modulation of the immune response
WO2008124086A2 (en) * 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
WO2009003145A1 (en) 2007-06-26 2008-12-31 University Of Miami Antibody-endostatin fusion protein and its variants
KR101759460B1 (ko) * 2007-09-21 2017-07-18 더 리전트 오브 더 유니버시티 오브 캘리포니아 표적화된 인터페론이 강력한 아폽토시스 및 항-종양 활성을 발휘함
WO2010036918A2 (en) 2008-09-26 2010-04-01 University Of Massachusetts Intracellular dna receptor
ES2547121T3 (es) 2008-12-08 2015-10-01 Complix N.V. Proteínas de superhélice antiparalela de una sola cadena
ES2534085T3 (es) 2009-08-17 2015-04-17 Roche Glycart Ag Inmunoconjugados dirigidos
CN102497885A (zh) 2009-09-10 2012-06-13 赛托斯生物技术公司 白介素-1β突变蛋白偶联物在糖尿病治疗中的用途
EP2496607B1 (en) * 2009-11-02 2017-09-27 The Regents of The University of California Vault complexes for cytokine delivery
SG188160A1 (en) * 2009-12-23 2013-03-28 Gradalis Inc Furin-knockdown and gm-csf-augmented (fang) cancer vaccine
CA2796706A1 (en) * 2010-04-22 2011-10-27 The Medical Research, Infrastructure, And Health Services Fund Of The Te L Aviv Medical Center High affinity leptins and leptin antagonists
CN102372780A (zh) * 2010-08-23 2012-03-14 上海市计划生育科学研究所 抗人绒毛膜促性腺激素抗体-白介素2融合蛋白的制备及其应用
WO2012170072A1 (en) 2011-06-06 2012-12-13 Immungene, Inc. Engineered antibody-tnfsf member ligand fusion molecules
NZ756727A (en) 2011-10-28 2022-12-23 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
CA2861927C (en) 2012-01-20 2021-01-26 Vib Vzw Targeted mutant alpha-helical bundle cytokines
HUE049945T2 (hu) 2012-03-03 2020-11-30 Immungene Inc Módosított antitest-interferon mutáns fúziós molekulák
EP3212216A4 (en) * 2014-10-29 2018-04-18 Teva Pharmaceuticals Australia Pty Ltd Interferon alpha2b variants

Also Published As

Publication number Publication date
US10640542B2 (en) 2020-05-05
CA2917937C (en) 2022-11-01
JP6580037B2 (ja) 2019-09-25
AU2018203868A1 (en) 2018-06-21
US20180155404A1 (en) 2018-06-07
EP3022305B1 (en) 2017-11-01
WO2015007536A3 (en) 2015-03-19
US20230054612A1 (en) 2023-02-23
SG11201600163VA (en) 2016-02-26
EP3299466B1 (en) 2019-09-11
JP6853317B2 (ja) 2021-03-31
US12410222B2 (en) 2025-09-09
CN105705641A (zh) 2016-06-22
BR112016001036A2 (pt) 2017-10-24
EP3022305A2 (en) 2016-05-25
DK3299466T3 (da) 2019-11-18
BR112016001036B1 (pt) 2023-02-23
AU2018203868B2 (en) 2019-12-05
JP2020002155A (ja) 2020-01-09
ES2757501T3 (es) 2020-04-29
JP2016525516A (ja) 2016-08-25
CN110835376B (zh) 2023-08-04
WO2015007536A2 (en) 2015-01-22
AU2014292371A1 (en) 2016-02-04
KR20160108291A (ko) 2016-09-19
EP3299466A1 (en) 2018-03-28
AU2014292371B2 (en) 2018-03-29
SG10201808738WA (en) 2018-11-29
CA2917937A1 (en) 2015-01-22
US11358997B2 (en) 2022-06-14
IL243451A0 (en) 2016-03-31
HK1252831A1 (en) 2019-06-06
CN105705641B (zh) 2021-07-13
KR102322510B1 (ko) 2021-11-08
IL243451B (en) 2019-10-31
CN110835376A (zh) 2020-02-25
MX375441B (es) 2025-03-06
ES2657060T3 (es) 2018-03-01
US20190010199A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
MX2016000611A (es) Fusocinas que implican citocinas con una afinidad de union al receptor considerablemente menor.
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
EP3794044A4 (en) DOUBLE BINDING UNIT
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
DK3292137T3 (da) Proteiner specifikke for cd137
CL2016000460A1 (es) Proteínas de unión al antígeno gitr
MA41313A (fr) Anticorps de liaison de la protéine april modifiés
SI3313879T1 (sl) Protitelesa z antitransferinskim receptorjem s prilagojeno afiniteto
MA47323A (fr) Protéines de liaison icos
BR112017011932A2 (pt) ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso?
IL285146A (en) Methods of purifying fc-containing proteins
UY32501A (es) Anticuerpo antagonista específico para el heterodímero alfa4-beta7
MX380520B (es) Anticuerpos receptores de antitransferina y métodos de uso.
EP2850103A4 (en) ST2-ANTIGEN-BINDING PROTEINS
MX2013013832A (es) Proteínas de unión receptoras fc.
EP2864358A4 (en) ANTIGENBINDING PROTEINS FOR BINDING CCR-2
DK3250586T3 (da) Hidtil ukendte proteiner, som er specifikke for angiogenese
CL2016000219A1 (es) Proteinas de fusión terapéutica.
EP3917952A4 (en) CD44-SPECIFIC ANTIBODIES
PL3004167T3 (pl) Białka wiążące antygen receptora onkostatyny m
EA201690992A1 (ru) Антитела, специфичные к fcrn
MX377052B (es) Antagonistas duales de receptores de neurocinina-1 (nk-1) / neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales.
IL269100A (en) Stabilized protein-bound cannabinoid compositions
SI3200822T1 (sl) Vezavne molekule, posebno antiteles, vezanih na L1CAM (CD171)
HUE063435T2 (hu) Eljárások rekombináns fehérjék mannóztartalmának növelésére

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: SULZER MANAGEMENT AG

FG Grant or registration